Belgian biopharma firm Cardio3 BioSciences has named Warren Sherman as its chief medical officer.
Sherman has over 30 years’ cardiology experience, with a focus on cell-based therapies for treating patients post-myocardial infarction and with heart failure.
He will assume the role at the cardiovascular disease-focused company from November 1.
He joins from Columbia University Medical Center, where he served in numerous roles including director of stem cell research and regenerative medicine and interventional cardiologist.
Sherman said: “I am thrilled to be joining Cardio3 BioSciences as chief medical officer at such an exciting time in its clinical development phase.
“The accomplishments of this young and dynamic company are remarkable, and it is an enormous opportunity for me to be part of the most promising project in the fields of cell therapy and other treatments for cardiovascular diseases.”
Sherman is also founder of the Cardiovascular Research Foundation’s international conference on cell therapy for cardiovascular disease (IC3D), a meeting for healthcare experts dedicated to the evolving file of cell-based therapies for the repair and regeneration of cardiac and vascular disease.
Christian Homsy, CEO of Cardio3 BioSciences, added: “We are very pleased to be able to count on Warren Sherman’s expertise in clinical application, as well as his renowned scientific outreach for the further development of Cardio3 BioSciences’ future projects in regenerative therapies and cardiovascular diseases.”